← Leaderboards
Scott William Cousins
Eyedesis Biosciences, Llc
$1,710,648
Attributed
$1,710,648
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $750K · FY2017–24$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,710,648 · 2
By mechanism
R44$1,485,618 · 1
R41$225,030 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Lynn Briscoe · Leidos Biomedical Research, Inc.$110,540,429
- Ted Ross · University Of Georgia$68,763,143
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$57,713,529
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Research focus
Pre-ClinicalCellsIn VitroPharmaceutical PreparationsToxicologyVisionElderlyIntravitreal InjectionLeadNovel TherapeuticsProductionSmall MoleculeApplications GrantsBiological SciencesEffective TherapyBlindnessFormulationGrowthDesignIn VivoDoseMacular DegenerationBiological Response Modifier TherapyBiological Availability
Grant awards (3)
Mitochondrial-Targeted Therapy for Macular Degeneration$735,619
R44 · FY2024 · EY · contact PI
Mitochondrial-Targeted Therapy for Macular Degeneration$749,999
R44 · FY2023 · EY · contact PI
Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases$225,030
R41 · FY2017 · EY · contact PI